Genzyme Biosurgery, a division of Genzyme Corp., disputes a quoted source in an article in the Dec. 12, 2003, issue of BioWorld Today. In the article, Matthew Shive, vice president, product development at Biosyntech, stated that the Genzyme Biosurgery product Carticel produces only "fibrocartilage." Genzyme said Carticel, which is FDA approved, has demonstrated the ability to produce hyaline cartilage, which is chemically and structurally similar to genuine articular cartilage. Furthermore, Carticel's label states: "Studies have shown that the implantation of Carticel can result in the development of hyaline cartilage."